d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis

Journal of Carcinogenesis

Volumn 8, Issue , 2009, Pages

  Rabi, Thangaiyan ^a   Bishayee, Anupam ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Apoptosis; d Limonen; Docetaxel; DU 145; Prostate cancer; Reactive oxygen species

Indexed keywords

CASPASE; CYTOCHROME C; DOCETAXEL; GLUTATHIONE; LIMONENE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; METASTASIS POTENTIAL; PROSTATE CANCER; PROTEIN EXPRESSION; SENSITIZATION; WESTERN BLOTTING;

EID: 67649484490     PISSN: None     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.51368     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2006, CA. Cancer J Clin 2006;56:10&30.
2. Bracarda S, de Cobelli 0, Greco C, Prpyer-Galetti T, Valdagni R, Gatha G, et al. Cancer of the prostate. Crit Rev Oncol Hematol 2005;38:379-96.
3. D'Andrea GM, Seidman AD. Docetaxel and paclitaxel in breast cancer therapy: Present status and future prospects. Semin Oncol 1997;24:27-44.
4. Gamucci T, D'Ottavio AM, Magnolfi E, Barduagni-M, Vaccaro A, Sperduti I. et al. Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 2007;97:1040-5.
5. Berthold DR, Pond GR, Soban F, De WR, Elsenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in theTAX 327 study. J Clin Oncol 2008;26:242-5.
6. Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec 2001;1:195-211.
7. Geney R, Ungureanu M, Li D, Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med 2002;40:918-25.
8. Petrylak D. Therapeutic options in androgen-independent prostate cancer: Building on docetaxel. BJU Int 2005;96:41-6.
9. Elegbede JA, Elson CE, Qureshi A, Tanner MA, Gould MN. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Cancinogenesis 1984;5:661-4.
10. Kaji I, Tatsuta M, Iishi H, Baba M, Inoue A, Kasugai H. Inhibition by D-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not, involve P2I RAS plasma membrane association. Int J Cancer 2001:93:441-4.
11. Nakaizumi A, Baba M, Uehara H, Lishi H, Tatsura M. d-limonene inhibits, N-nitrosobis (2-oxopropyl) amine induced hamster pancreatic carcinogenesis. Cancer Lett 1997;1 17:99:103.
12. McNamee D. d-Limonene trial in cancer. Lancet 1993;342:801-5.
13. Vigushin DM, Poon GK, BoddyA, English J, Halbert GW, Pagonis C, et al. Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Research Campaign Phase 1/11 Clinical Trials Committee. Cancer Chemother Pharmacol 1998;42:111-7.
14. Jirtle RL, Haag JD, Ariazi EA. Gould MN. Increased mannose 6-phosphate/ insulin-like growth factor 11 receptor and transforming growth factor beta I levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993;53:3849-52.
15. Bourne HR, Sanders CA, McCormick F. The GTPas superfamily: Conserved structure and molecular mechanism. Nature 1991;349:117-27.
16. Haag JD, Lindstrom MJ, Gould MN. Limonene induced regression of mammary carcinomas. Cancer Res 1992;52:4021-6.
17. Rabi T, Ramachandran C, Fonseca HB, Alomo A, Melnick SJ, Escalon E. Novel drug amooranin induces apoptosis through caspase activity in human breast carcinoma cell lines. Breast Cancer Res Treat 2003;80:321-30.
18. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-droxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1191-8.
19. Finley CA, Hinds PW, Levine AJ. The p53 proto oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
20. Su Piot S, Hill RP. Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993-9.
21. Dumaz N, Meek DW. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 1999;18: 7002-10.
22. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis: A growth regulator and a therapeutic target. Cell Tissue Res 2000;301:153-62.
23. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005; 12:19-47.
24. Klein EA, Thomson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143-9.
25. Saleem M, Adhami VM, Siddhiqui IA, Mukhtar H. Tea beverage in chemoprevention of prostate cancer:A mini-review. Nutr Cancer 2003;47:13-23.
26. Yvon AC, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Am Soc Cell Biol 1999; 10:947-59.
27. Lyseng-Williamson KA, Fenton C. Docetaxel:A review of its use in metastatic breast cancer. Drugs 2005;65:2513-31.
28. Legrier ME, Oudard S, Judde JG. Potentiation of antitumor activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007;96:269-76.
29. Beer TM, El-Geneidi M, Eilers KM. Docetaxel in the treatment of prostate cancer. Expert Rev Anticancer Ther 2003;3:261-8.
30. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH. Gene expression profiling revealed novel mechanism of action of docetaxel and Furtulon in prostate cancer cells. BMC Cancer 2005;5:7-14.
31. Sun J. d-Limonene: safety and clinical applications.Altern Med Rev 2007; 12:259-64.
32. Ceruti PA. Prooxidant states and tumor promotion. Science 1985;227:375-81.
33. Bohler T, Waiser J, Hepburn H, Gaedeke J, Lehmann C, Hambach P, et al. TNF-alpha and IL-I alpha induce apoptosis in subcoufluent rat mesangial cells: Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messeggers. Cytokine 2000;12:986-91.
34. 2-induced apoptosis with acid sphingomyelinase activation. Biochim Biophys Acta 2001;1533:47-54.
35. Bauer G. Reactive oxygen and nitrogen species: Efficient, selective, and interactive signal during intercellular induction of apoptosis. Anticancer Res 2000;20:4115-39.
36. Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P, et a;. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol 2008;217:494-501.
37. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28:3-7.
38. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3-7.